ភាគហ៊ុន Novavax ទើបតែឡើងដល់ 35%៖ ស្វែងយល់ពីមូលហេតុ

Shares of Novavax Inc (NASDAQ: NVAX) tanked nearly 35% in extended trading on Monday after the biotech company reported thoroughly disappointing results for its fiscal second quarter and lowered its annual sales outlook by 50%.

Novavax Q2 financial highlights

• បាត់បង់ 510.5 លានដុល្លារធៀបនឹងឆ្នាំមុន 352 លានដុល្លារ
• Per-share loss climbed from $4.75 to $6.53
• ការលក់បានកើនឡើង 38% ពីមួយឆ្នាំទៅមួយឆ្នាំដល់ 185.9 លានដុល្លារ
• Consensus was EPS of $5.54 on $1.02 billion in sales
• R&D expenses were nearly cut in half from last year

U.S. FDA authorised the Novavax COVID-19 vaccine for emergency use in July. In the សេចក្តីប្រកាសព័ត៌មានស្តីពីប្រាក់ចំណូល, CEO Stanley Erck said:

តើអ្នកកំពុងស្វែងរកព័ត៌មានរហ័សព័ត៌មានជំនួយក្តៅនិងការវិភាគទីផ្សារមែនទេ?

ចុះឈ្មោះសម្រាប់ព្រឹត្តិប័ត្រ Invezz ថ្ងៃនេះ។

We’re distributing our vaccine globally and have gained positive momentum as we move into the remainder of 2022 and into 2023. Through continued expansions to our label for adolescents and boosting out vaccine’s competitive product profile, we’re confident it’ll play an important role in the long-term COVID-19 landscape.

ភាគហ៊ុនរបស់ Novavax ឥឡូវនេះបានធ្លាក់ចុះជាង 70% សម្រាប់ឆ្នាំនេះ។

Novavax shares down on lowered guidance

Novavax ended the quarter with $1.40 billion in cash and equivalents (including restricted cash). For fiscal 2022, it now forecasts up to $2.3 billion in revenue only down from $4.0 billion to $5.0 billion it had guided for previously.

នៅក្នុងដាច់ដោយឡែកមួយ unsigned statement, the management cited “several evolving market dynamics” for the weak guidance and said:

We’ve shipped over 23 million doses since the beginning of July and, while in some cases delivery timing may be pushed into 2023, we don’t expect total contracted demand to change under the majority of our Advance Purchase Agreements.

Heading into the earnings print, Wall Street had a consensus "លើសទម្ងន់" rating on Novavax shares.